
Chairman's Note



Immunotherapy has become a part of the standard-of-care treatment for patients with certain cancers. In this issue of the *American Journal of Hematology/Oncology*, a peer-reviewed resource for oncology education and the official journal of Physicians' Education Resource®, LLC, we feature 2 articles on immunotherapy: In the first, Elizabeth A. Mittendorf, MD, PhD, and Kelly K. Hunt, MD, focus on emerging results from clinical trials evaluating immunotherapy in breast cancer. In the second, Sarah B. Goldberg, MD, summarizes progress to date regarding the development of immunotherapies targeting the PD-1 axis for non-small cell lung cancer (NSCLC).

In the past decade, advances in the treatment of NSCLC have included the approval of antiangiogenesis inhibitors such as bevacizumab and ramucirumab, and tyrosine kinase inhibitors (TKIs) such as erlotinib. Some success has been observed in trials of antiangiogenesis inhibitors combined with EGFR TKIs in the general population. In this issue, Edward S. Kim, MD, details the combination trials that are currently ongoing in the EGFR mutation-positive population.

Bobby C. Liaw, MD, and William K. Oh, MD, explore the current controversy on the use of docetaxel for metastatic hormone-sensitive prostate cancer, including a review of the results of the recently published CHAARTED and STAMPEDE trials.

Carlie K. Thompson, MD, Martin Eklund, PhD, and Laura J. Esserman, MD, MBA, review the "great mammography debate," and propose that controversies in breast cancer screening be settled once and for all with a modern-era screening trial.

Our CME article this month reviews factors that impact adherence to oral cancer therapies and some strategies for improving adherence, with the goal of improving outcomes in the real-world setting.

Michael J. Hennessy, Sr
Chairman and Chief Executive Officer



MH

Michael J. Hennessy Associates, Inc.

The content of this publication is for general information purposes only. The reader is encouraged to confirm the information presented with other sources. *American Journal of Hematology/Oncology* makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this publication and expressly disclaims liability for any errors and omissions that may be presented in this publication. *American Journal of Hematology/Oncology* reserves the right to alter or correct any error or omission in the information it provides in this publication, without any obligations. *American Journal of Hematology/Oncology* further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this publication. The views expressed in this publication are those of the authors and do not necessarily reflect the opinion or policy of *American Journal of Hematology/Oncology*.